Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major metastatic HER2-positive breast cancer markets are expected to exhibit a CAGR of 1.18% during 2023-2034.

The metastatic HER2-positive breast cancer market has been comprehensively analyzed in this report titled "Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer is an advanced stage of breast cancer characterized by the presence of HER2 protein overexpression. It tends to be more aggressive than other forms of cancer due to its accelerated growth and increased likelihood of spreading beyond the breast tissue. The symptoms of this illness may include a palpable lump in the breast or underarm, alterations in breast shape or size, skin dimpling, nipple changes, persistent pain, and bone fractures. As the cancer advances, it can spread to distant organs, such as the brain, bones, lungs, or liver, causing further complications. The diagnosis of metastatic HER2-positive breast cancer typically requires a combination of clinical findings and physical investigations. The healthcare provider will also perform numerous diagnostic procedures, including a mammogram or ultrasound, a biopsy of the tumor tissue to confirm HER2 positivity, and imaging studies to determine the extent of metastasis.

The increasing incidences of genetic variations in the BRCA1 and BRCA2 genes, resulting in uncontrolled growth and division of abnormal cells that originate in the breast tissue, are primarily driving the metastatic HER2-positive breast cancer market. In addition to this, the inflating utilization of innovative approaches, such as antibody-drug conjugates and immune checkpoint inhibitors, which help in harnessing the body's immune response to combat cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, including immunotherapies, bisphosphonates, and pain management strategies, aimed at enhancing patients' overall well-being and mitigating treatment-related complications, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, since they involve tailoring treatments based on the genetic makeup of the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive procedures, such as radiofrequency ablation and cryoablation to precisely target and eliminate tumor masses in individuals suffering from the illness is also augmenting the market growth. Furthermore, the escalating application of gene-targeting treatments that aim to correct or inhibit the overexpression of the HER2 gene is expected to drive the metastatic HER2-positive breast cancer market during the forecast period.

This report provides an exhaustive analysis of the metastatic HER2-positive breast cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic HER2-positive breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic HER2-positive breast cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the metastatic HER2-positive breast cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the metastatic HER2-positive breast cancer market

Competitive Landscape:

This report also provides a detailed analysis of the current metastatic HER2-positive breast cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the metastatic HER2-positive breast cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the metastatic HER2-positive breast cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the metastatic HER2-positive breast cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with metastatic HER2-positive breast cancer across the seven major markets?
• What is the size of the metastatic HER2-positive breast cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of metastatic HER2-positive breast cancer?
• What will be the growth rate of patients across the seven major markets?

Metastatic HER2-Positive Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for metastatic HER2-positive breast cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic HER2-positive breast cancer market?
• What are the key regulatory events related to the metastatic HER2-positive breast cancer market?
• What is the structure of clinical trial landscape by status related to the metastatic HER2-positive breast cancer market?
• What is the structure of clinical trial landscape by phase related to the metastatic HER2-positive breast cancer market?
• What is the structure of clinical trial landscape by route of administration related to the metastatic HER2-positive breast cancer market?

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.